These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 14674790)
1. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. Terziivanov D; Bozhinova K; Dimitrova V; Atanasova I Clin Pharmacokinet; 2003; 42(15):1393-409. PubMed ID: 14674790 [TBL] [Abstract][Full Text] [Related]
2. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2? De Kesel PM; Lambert WE; Stove CP Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821 [TBL] [Abstract][Full Text] [Related]
3. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Faber MS; Fuhr U Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794 [TBL] [Abstract][Full Text] [Related]
4. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842 [TBL] [Abstract][Full Text] [Related]
5. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Fuhr U; Rost KL Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694 [TBL] [Abstract][Full Text] [Related]
7. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Zaigler M; Rietbrock S; Szymanski J; Dericks-Tan JS; Staib AH; Fuhr U Int J Clin Pharmacol Ther; 2000 May; 38(5):235-44. PubMed ID: 10839467 [TBL] [Abstract][Full Text] [Related]
8. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. Thai C; Tayo B; Critchley D Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1279-1289. PubMed ID: 33951339 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Perera V; Gross AS; Xu H; McLachlan AJ J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488 [TBL] [Abstract][Full Text] [Related]
10. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG Eur J Clin Pharmacol; 2000 May; 56(2):159-65. PubMed ID: 10877011 [TBL] [Abstract][Full Text] [Related]
11. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Simon T; Becquemont L; Hamon B; Nouyrigat E; Chodjania Y; Poirier JM; Funck-Brentano C; Jaillon P Br J Clin Pharmacol; 2001 Nov; 52(5):601-4. PubMed ID: 11736870 [TBL] [Abstract][Full Text] [Related]
12. Why dried blood spots are an ideal tool for CYP1A2 phenotyping. De Kesel PM; Lambert WE; Stove CP Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692 [TBL] [Abstract][Full Text] [Related]
13. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258 [TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Spigset O; Hägg S; Söderström E; Dahlqvist R Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755 [TBL] [Abstract][Full Text] [Related]
15. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Darwish M; Kirby M; Robertson P; Hellriegel ET Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219 [TBL] [Abstract][Full Text] [Related]
16. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575 [TBL] [Abstract][Full Text] [Related]
17. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488 [TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. Kisor DF; Watling SM; Zarowitz BJ; Jelliffe RW Clin Pharmacokinet; 1992 Jul; 23(1):62-8. PubMed ID: 1617859 [TBL] [Abstract][Full Text] [Related]
19. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239 [TBL] [Abstract][Full Text] [Related]
20. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]